[Endothelin1 and angiotensin II in preeeclampsia]. Revista de Investigacion Clinica; Organo del Hospital de Enfermedades de la Nutricion. 2007, 59 (1):
Compeer MG, Meens MJ. Endothelin-1, an Endogenous Irreversible Agonist in Search of an Allosteric Inhibitor. Mol Cell Pharmacol. 2009, 1 (5): 246–257. Rosenbaum
目前發現具有EGFR突變型的NSCLC癌細胞會對tyrosine kinase inhibitor產生抗藥作用,這個抗藥作用可能來自於其中細胞大量的endothelin表現,進而使腫瘤組織血管收縮,降低了抗癌藥物的灌流,產生類似抗藥性的效果。 Kathryn M. Ferguson, Mitchell B.
Trump DL, Payne H, Miller K, et al. Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients